The acthib omnihib market has seen considerable growth due to a variety of factors.
• In recent years, the acthib, omnihib market has seen a XX% (HCAGR) increase. Predictions indicate that it will surge from $XX million in 2024 to $XX million in 2025, showcasing a compound annual growth rate (CAGR) of XX%.
The historical growth is largely due to the expansion of international immunization efforts, higher pediatric vaccination rates, an increasing number of hib disease outbreaks, the increased acceptance of combination vaccines, as well as an enhancement in public understanding of diseases that vaccines can prevent.
The acthib omnihib market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the acthib, omnihib market size is predicted to witness a CAGR of XX% and is anticipated to reach a value of $XX million by 2029.
This growth surge during the forecast period can be credited to the increasing awareness and efforts to regulate hib infections, rise in hib-related infections, enhanced immunization, growing use of antibiotics and glucocorticoids, as well as the increasing prevalence of chronic diseases. Major trends in the forecast period encompass progressions in pediatric vaccinations, improvements in vaccine technology, innovation and technological developments, the launch of new products, and advancements in vaccine delivery systems.
The escalating incidence of haemophilus influenzae type b (Hib) infections appears to be driving the expansion of the acthib, omnihib market. Severe bacterial infections brought about by Haemophilus influenzae type b result in illnesses such as meningitis, pneumonia, and epiglottitis, mainly in young children. The surge in haemophilus influenzae type B (Hib) infections may be linked to reasons like declining vaccination rates, rise in antibiotic resistance, and inadequate healthcare access in some regions. ActHIB, omniHIB are utilised for haemophilus influenzae type B (Hib) infections as these provoke the immune system to identify and combat the Haemophilus influenzae type b bacteria. For instance, in a news report issued by the European Centre for Disease Prevention and Control (ECDC), a government agency located in Sweden, in July 2024, a marked rise in authenticated instances of invasive Haemophilus influenzae disease was documented in 2022, with a total of 3,967 cases, significantly surpassing the 1,694 cases reported in 2021. Consequently, the growing prevalence of Haemophilus influenzae type b (Hib) infections is bolstering the acthib, omnihib market.
The acthib, omnihib market covered in this report is segmented –
1) By Type Of Vaccine: Monovalent Hib Vaccines, Combination Vaccines
2) By Clinical Indication: Haemophilus Influenzae Type B (HIB) Infection
3) By Age Group: Infants And Toddlers, Adults
4) By End-User: Hospitals And Clinics, Retail Pharmacies
The acthib, omnihib market is primarily observing a rising emphasis on creating innovative combined vaccines, aimed at providing enhanced protection against multiple diseases while minimizing the need for numerous immunization shots. A prime example of such vaccines is a conjugate vaccine, which synergizes a bacterial polysaccharide with a protein to boost immune responses. To exemplify, Sanofi SA, a biopharmaceutical firm hailing from France, secured approval for amendments to the Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (ActHIB) in October 2022. This development is crucial in refining safety measures for vaccine application. The changes proposed for the package insert and box or container labels aim to minimize the potential for reconstitution errors during the process of vaccine preparation.
Major companies operating in the acthib, omnihib market include:
• Sanofi SA
North America was the largest region in the acthib, omnihib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acthib, omnihib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.